BIOMAT Database Logo BIOMAT Database Logo

Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. 2009

P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Institute of Neurology, University Magna Graecia, Catanzaro, Italy.

OBJECTIVE The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GM(V)) and white matter (WM(V)) volumes. RESULTS The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy. CONCLUSIONS Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.

UI MeSH Term Description Entries
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005677 G(M1) Ganglioside A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis. GM1 Ganglioside,Monosialosyl Tetraglycosyl Ceramide,GM1a Monosialoganglioside,Ceramide, Monosialosyl Tetraglycosyl,Ganglioside, GM1,Monosialoganglioside, GM1a,Tetraglycosyl Ceramide, Monosialosyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001284 Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. Atrophies
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D020529 Multiple Sclerosis, Relapsing-Remitting The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914) Multiple Sclerosis, Acute Relapsing,Relapsing-Remitting Multiple Sclerosis,Acute Relapsing Multiple Sclerosis,Remitting-Relapsing Multiple Sclerosis,Multiple Sclerosis, Relapsing Remitting,Multiple Sclerosis, Remitting-Relapsing,Relapsing Remitting Multiple Sclerosis,Remitting Relapsing Multiple Sclerosis

Related Publications

P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis.
May 2000, Annals of neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
January 2003, Neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.
April 2016, Neurology(R) neuroimmunology & neuroinflammation,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Seroconversion of anti-GM1 antibodies in patients with amyotrophic lateral sclerosis.
August 2004, Neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Post-infectious ophtalmoparesis associated with anti-GM1 but not with anti-GQ1b antibodies.
September 2001, European journal of neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis.
March 2004, Ideggyogyaszati szemle,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Clinical syndromes associated with anti-GM1 antibodies.
September 1993, Seminars in neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
MR correlates of cerebral atrophy in patients with multiple sclerosis.
August 2002, Journal of neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
November 2015, Journal of neurology,
P Valentino, and A Labate, and R Nisticò, and D Pirritano, and A Cerasa, and M Liguori, and L Bastone, and L Crescibene, and A Quattrone
Multiple sclerosis relapses are not associated with exercise.
February 2012, Multiple sclerosis (Houndmills, Basingstoke, England),
Copied contents to your clipboard!